MAY 0 2 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Francois Shutze et al.	Group Art Unit: 1617
Application No.: 10/532,041	Examiner: CARLIC K HUYNH
Filing Date: June 23, 2006	Confirmation No.: 5818
Title: PHARMACEUTICAL COMPOSITION COMBINING TENATOPRAZOLE AND AN ANTI-INFLAMMATORY AGENT)))

COPENDING INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Enclosed is a Copending Information Disclosure Statement (IDS) and accompanying form PTO-1449 for the above-identified patent application. \bowtie No additional fee for submission of an IDS is required. The fee of \$ 180 as set forth in 37 C.F.R. § 1.17(p) is also enclosed. A statement under 37 C.F.R. § 1.97(e) is also enclosed. A statement under 37 C.F.R. § 1.97(e), and the fee of \$ 180 as set forth in 37 C.F.R. § 1.17(p) are also enclosed. to Deposit Account No. 02-4800 for the fee due. A check in the amount of ______ is enclosed for the fee due. to credit card for the fee due. Form PTO-2038 is attached. 冈 The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate. Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date 1 May 2007

By: 7. M. - Conf.

Melissa M. Haywoth Registration No. 45774

P.O. Box 1404 Alexandria, VA 22313-1404 703 836 6620

Attorney Docket No. <u>1032013-000121</u> IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re Patent Application of)
Francois Shutze et al.) Group Art Unit: 1617
Application No.: 10/532,041) Examiner: CARLIC K HUYNH
Filing Date: June 23, 2006	Confirmation No.: 5818
Title: PHARMACEUTICAL COMPOSITION COMBINING TENATOPRAZOLE AND AN ANTI-INFLAMMATORY AGENT	<i>)</i>))

COPENDING INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

form I	Enclosed is a Copending Inform PTO-1449 for the above-identified	nation Disclosure Statement (IDS) and accompanying patent application.				
\boxtimes	No additional fee for submission	No additional fee for submission of an IDS is required.				
	The fee of \$ 180 as set forth in	37 C.F.R. § 1.17(p) is also enclosed.				
	A statement under 37 C.F.R. §	1.97(e) is also enclosed.				
	A statement under 37 C.F.R. § 37 C.F.R. § 1.17(p) are also end	1.97(e), and the fee of \$ 180 as set forth in closed.				
	Charge to De	posit Account No. 02-4800 for the fee due.				
	A check in the amount of	is enclosed for the fee due.				
	Charge to cre	dit card for the fee due. Form PTO-2038 is attached.				
	37 C.F.R. §§ 1.16, 1.17 and 1.2	ed to charge any appropriate fees under 1 that may be required by this paper, and to credit count No. 02-4800. This paper is submitted in				
	Re	espectfully submitted,				
	В	JCHANAN INGERSOLL & ROONEY PC				
Date	1 May 2007 By	Melissa M. Haywoodh Registration No. 45774				

P.O. Box 1404 Alexandria, VA 22313-1404 703 836 6620



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
Francois Shutze et al.)	Group Art Unit: 1617
Application No.: 10/532,041)	Examiner: CARLIC K HUYNH
Filed: June 23, 2006)	Confirmation No.: 5818
For: PHARMACEUTICAL COMPOSITION COMBINING TENATOPRAZOLE AND AN ANTI-INFLAMMATORY AGENT)))))	

COPENDING INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56 and the Examiner's request in the Office Action dated 11 September 2006 for copending application U.S. Serial No. 10/532,114, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed. However, copies of the listed U.S. patents and U.S. patent application publications are not enclosed since it is no longer required.

The documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Copending Information Disclosure Statement Application No. 10/532,041
Attorney Docket No. 1032013-000121
Page 2

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: Man 2007

Bv:

Melissa M. Hayworth

Registration No. 45774

P.O. Box 1404 Alexandria, VA 22313-1404 703 836 6620 Substitute for form 1449/PTO & 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	Complete if Known
Application Number	10/532,041
Filing Date	June 23, 2006
First Named Inventor	Francois Shutze et al.
Examiner Name	CARLIC K HUYNH
Attorney Docket No.	1032013-000121

OFFE	
(Ro	
MAY 0 2 2007	
\ <u>R</u> <u>\\</u>	
(F)	
PADEMARTI	

Sheet	1	of	1
OHEGI	,	O1	

U.S. PATENT DOCUMENTS					
Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)	
	7,034,038		Cohen et al.	04-25-2006	
	2006-0194832	A1	Cohen et al.	08-31-2006	
	2007-0066659	A1	Schutze et al.	03-22-2007	
	2006-0241136	A1	Schutze et al.	10-26-2006	
	···				

	FOREIGN PATENT DOCUMENTS										
	STATUS										
Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec
\											
											
-											

	NON-PATENT LITERATURE DOCUMENTS					
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	U.S. Serial No. 10/561,844 "Monohydrated Sodium Salt of S-Tenatoprazole and the Use Thereof in Therapy",					
	filed December 22, 2005, attorney docket no. 1032013-000133.					

Examiner Signature	Date Considered	